{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:27:44Z","timestamp":1792103264348,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012331","name":"Agentschap Innoveren en Ondernemen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ebiom.2023.104597","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T23:04:31Z","timestamp":1683155071000},"page":"104597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-4759","authenticated-orcid":false,"given":"Elise","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caro","family":"Verbrugghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Devloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"De Clippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Jochmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"De Bleser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Weynand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Compernolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0052-8852","authenticated-orcid":false,"given":"Hendrik B.","family":"Feys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ebiom.2023.104597_bib1","doi-asserted-by":"crossref","DOI":"10.2196\/22117","article-title":"Human-animal interaction and the emergence of SARS-CoV-2","volume":"6","author":"Hassani","year":"2020","journal-title":"JMIR Public Health Surveill"},{"issue":"7181","key":"10.1016\/j.ebiom.2023.104597_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2023.104597_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/d41586-022-04423-8","article-title":"Even after COVID, the world's vaccine strategy is failing","volume":"612","author":"Berkley","year":"2022","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ebiom.2023.104597_bib4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"10289","key":"10.1016\/j.ebiom.2023.104597_bib5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104597_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01724-2021","article-title":"Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma","volume":"59","author":"Devos","year":"2021","journal-title":"Eur Respir J"},{"issue":"21","key":"10.1016\/j.ebiom.2023.104597_bib7","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with Covid-19","volume":"385","author":"Korley","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104597_bib8","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/hematology.2021000299","article-title":"Passive immune therapies: another tool against COVID-19","volume":"2021","author":"Estcourt","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ebiom.2023.104597_bib9","article-title":"Convalescent plasma in critically ill patients with Covid-19","author":"Estcourt","year":"2021","journal-title":"medRxiv"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104597_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/bjh.17266","article-title":"Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies","volume":"192","author":"Betrains","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104597_bib11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","article-title":"Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis","volume":"36","author":"Hueso","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.ebiom.2023.104597_bib12","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for Covid-19 with convalescent plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104597_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijid.2021.02.054","article-title":"Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study","volume":"105","author":"Tworek","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104597_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad088","article-title":"COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from five randomized trials","author":"Levine","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104597_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ebiom.2023.104597_bib16","article-title":"Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis","author":"Senefeld","year":"2023","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104597_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104597_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104597_bib19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104597_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41385-022-00517-8","article-title":"Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines","volume":"15","author":"Mouro","year":"2022","journal-title":"Mucosal Immunol"},{"issue":"10282","key":"10.1016\/j.ebiom.2023.104597_bib21","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO International Standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104597_bib22","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1111\/trf.16652","article-title":"A\u00a0novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma","volume":"61","author":"Wouters","year":"2021","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104597_bib23","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.9.2000178","article-title":"First cases of coronavirus disease 2019 (COVID-19) in the WHO European region, 24 January to 21 February 2020","volume":"25","author":"Spiteri","year":"2020","journal-title":"Euro Surveill"},{"issue":"6579","key":"10.1016\/j.ebiom.2023.104597_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.abm8143","article-title":"Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry","volume":"375","author":"Park","year":"2022","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104597_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104705","article-title":"Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model","volume":"25","author":"Imbrechts","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ebiom.2023.104597_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105253","article-title":"The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters","volume":"198","author":"Abdelnabi","year":"2022","journal-title":"Antiviral Res"},{"issue":"43","key":"10.1016\/j.ebiom.2023.104597_bib27","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104597_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A\u00a0simple method of estimating fifty per cent ENDPOINTS12","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104597_bib29","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1038\/s41467-020-19684-y","article-title":"STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters","volume":"11","author":"Boudewijns","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104597_bib30","first-page":"424","article-title":"Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"6538","key":"10.1016\/j.ebiom.2023.104597_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1126\/science.abi8397","article-title":"The story behind COVID-19 vaccines","volume":"372","author":"Fauci","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104597_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"628","key":"10.1016\/j.ebiom.2023.104597_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A\u00a0phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"635","key":"10.1016\/j.ebiom.2023.104597_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"issue":"23","key":"10.1016\/j.ebiom.2023.104597_bib35","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104597_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7898","key":"10.1016\/j.ebiom.2023.104597_bib37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron","volume":"602","author":"Carreno","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104597_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.chom.2021.03.008","article-title":"SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera","volume":"29","author":"Kuzmina","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"28","key":"10.1016\/j.ebiom.2023.104597_bib39","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104597_bib40","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1080\/22221751.2020.1858177","article-title":"Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection","volume":"9","author":"Rosenke","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104597_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41423-020-0474-z","article-title":"Serum IgA, IgM, and IgG responses in COVID-19","volume":"17","author":"Ma","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ebiom.2023.104597_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104597_bib43","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41590-021-01028-7","article-title":"Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection","volume":"22","author":"Smith","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2023.104597_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.iccn.2020.102967","article-title":"Impact of COVID-19 on nursing time in intensive care units in Belgium","volume":"62","author":"Bruyneel","year":"2021","journal-title":"Intensive Crit Care Nurs"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104597_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000509546","article-title":"The impact of the COVID-19 pandemic and the associated Belgian governmental measures on Cancer screening, surgical Pathology and Cytopathology","volume":"88","author":"de Pelsemaeker","year":"2021","journal-title":"Pathobiology"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104597_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/vox.13060","article-title":"Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary","volume":"116","author":"Wouters","year":"2021","journal-title":"Vox Sang"},{"issue":"27","key":"10.1016\/j.ebiom.2023.104597_bib47","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.27.2100568","article-title":"SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data","volume":"26","author":"Nguyen","year":"2021","journal-title":"Euro Surveill"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104597_bib48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/vox.13239","article-title":"Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?","volume":"117","author":"Focosi","year":"2022","journal-title":"Vox Sang"},{"issue":"7918","key":"10.1016\/j.ebiom.2023.104597_bib49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41586-022-04895-8","article-title":"Enteric viruses replicate in salivary glands and infect through saliva","volume":"607","author":"Ghosh","year":"2022","journal-title":"Nature"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:24:21Z","timestamp":1762457061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":49,"alternative-id":["S2352396423001627"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104597","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104626","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104597"}}